For example, although inhibition of PCSK9 was causally associated with lower LDL cholesterol levels and lower risk of atherogenesis in SLE patients (Fang et al., 2018), statins had no benefit for atherogenesis in SLE patients (Schanberg et al., 2012; van Leuven et al., 2012). The gene discussed is PCSK9; the disease is systemic lupus erythematosus.